It is supposed that the clinical failure of 5-HT6R agents is a consequence of the fact that those anti-AD drug candidates have been designed as single-target molecules, whereas such a complex disease as AD involves many different signaling pathways that form the pathological network [15]. The gene discussed is HTR6; the disease is Alzheimer disease.